Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Biogen’s subsidiary announced pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals under an Agreement and Plan of Merger dated March 31, 2026. The communication states the tender offer has not yet commenced and that formal offer materials will be filed on Schedule TO when the offer begins. It directs Apellis securityholders to read the forthcoming offer documents and the solicitation/recommendation statement on Schedule 14D-9 carefully and to obtain those materials from the SEC or company websites. The filing includes customary forward-looking disclaimers and identifies social media posts made on March 31, 2026 as an exhibit.
Apellis Pharmaceuticals agreed to be acquired by Biogen through a cash tender offer and follow‑on merger. Biogen will offer Apellis stockholders $41.00 in cash per share plus a non‑transferable contingent value right (CVR) that can pay up to an additional $4.00 per share in cash if specified SYFOVRE® annual global net sales milestones are met. The implied upfront transaction value is approximately $5.6 billion. A tender offer will run for 20 business days, subject to customary conditions including a majority tender, antitrust clearance under the HSR Act and other standard closing conditions. Apellis’ board unanimously approved the deal and recommends stockholders tender their shares. Certain directors, executives and a major stockholder holding about 14% of Apellis shares signed a tender and support agreement to back the transaction.
Apellis Pharmaceuticals Schedule 13G/A amendment filed by The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report separately in reliance on SEC Release No. 34-39538.
The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Apellis Pharmaceuticals Chief Executive Officer Cedric Francois reported gift transfers of common stock. On March 11, 2026, entities associated with him made bona fide gifts totaling 129,738 shares, including a transfer of 64,869 shares to The Cedric Francois Irrevocable Trust of 2023 - 2.
After these gifts, he directly holds 425,968 shares. The filing also lists indirect holdings through several trusts, including 372,815 shares in The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares in The Cedric Francois Irrevocable Trust of 2023, 300,000 shares in The Francois Grossi Trust, and 234,411 shares in The Francois-DuBois Educational Trust.
Apellis Pharmaceuticals director Mikael Dolsten reported receiving new equity awards. On February 27, 2026, he was granted stock options for 24,135 shares at an exercise price of $20.96 per share, vesting in equal one-third installments annually over three years, subject to continued service.
He also received 14,312 shares of common stock as a restricted stock unit grant. This restricted stock unit will fully vest on the first anniversary of the grant date, or upon a later termination of his service as a director at his election, provided he continues serving as a director.
Apellis Pharmaceuticals, Inc. director Mikael Dolsten filed an initial statement of beneficial ownership on Form 3. This filing establishes him as an insider for reporting purposes, but it does not list any specific stock transactions or changes in his holdings.
Apellis Pharmaceuticals appointed Mikael Dolsten, M.D., Ph.D., to its Board of Directors as a Class I director, effective March 1, 2026. He will serve until the 2027 annual stockholder meeting or until a successor is elected and qualified.
The Board determined that Dr. Dolsten is independent under Nasdaq rules. Upon joining, he received an option grant with a Black‑Scholes value of $300,000, vesting in three equal annual installments, and RSUs valued at $300,000 that vest after one year, all subject to continued service and full acceleration upon a change in control.
Apellis Pharmaceuticals is a commercial-stage biotech focused on complement inhibition, with two marketed C3‑targeting drugs: SYFOVRE for geographic atrophy (GA) and EMPAVELI for rare blood and kidney diseases.
In 2025, Apellis generated $586.9 million in U.S. net product revenue from SYFOVRE and $102.4 million from EMPAVELI, plus $13.2 million in royalties from partner Sobi. Net income was $22.4 million for 2025, compared with net losses of $197.9 million in 2024 and $528.6 million in 2023.
The company is expanding SYFOVRE globally, including approval in Australia, and advancing next‑generation GA therapy by combining SYFOVRE with siRNA APL‑3007. For EMPAVELI, Apellis is growing nephrology indications such as C3 glomerulopathy, primary IC‑MPGN, FSGS and delayed graft function. A July 2025 royalty buy‑down with Sobi brought a $275.0 million upfront payment and a $25.0 million EMA approval milestone, monetizing ex‑U.S. systemic pegcetacoplan royalties. As of June 30, 2025, non‑affiliate equity market value was $1.8 billion, and common shares outstanding were 127,829,909 as of February 17, 2026.
RTW Investments, LP and its managing partner Roderick Wong, M.D. reported beneficial ownership of Apellis Pharmaceuticals, Inc. common stock on a Schedule 13G. They report beneficial ownership of 7,666,764 shares of common stock, representing 6.1% of the outstanding class based on 126,525,218 shares outstanding as of October 23, 2025.
Both reporting persons have shared voting and shared dispositive power over these 7,666,764 shares, with no sole voting or dispositive power. The shares are held by certain funds advised by RTW Investments, which have the right to receive dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Apellis.
Apellis Pharmaceuticals Chief Business & Strat Officer Mark DeLong reported a small stock sale mainly for tax purposes. On February 11, 2026, he sold 368 shares of Apellis common stock at $22.1537 per share to cover tax withholding tied to Restricted Stock Units released on February 10, 2026. After this transaction, he directly owned 114,591 shares of Apellis common stock.